Larimar Therapeutics
LRMR
116 hedge funds and large institutions have $180M invested in Larimar Therapeutics in 2025 Q2 according to their latest regulatory filings, with 30 funds opening new positions, 43 increasing their positions, 23 reducing their positions, and 17 closing their positions.
3,977% more call options, than puts
Call options by funds: $14.1M | Put options by funds: $347K
87% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 23
76% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 17
37% more capital invested
Capital invested by funds: $132M → $180M (+$48.2M)
13% more funds holding
Funds holding: 103 → 116 (+13)
2.32% more ownership
Funds ownership: 95% → 97.32% (+2.3%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$6.9M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$5.08M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$2.09M |
| 4 |
Two Sigma Advisers
New York
|
+$1.74M |
| 5 |
CM
Caption Management
Oklahoma City,
Oklahoma
|
+$1.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$13.1M |
| 2 |
Goldman Sachs
New York
|
-$5.88M |
| 3 |
Renaissance Technologies
New York
|
-$957K |
| 4 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$762K |
| 5 |
Morgan Stanley
New York
|
-$561K |
LRMR Hedge Fund Activity: Q2 2025 in Review
116 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Larimar Therapeutics (LRMR) for Q2 2025, worth a combined $180M — up 37% from $132M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new LRMR positions and 17 closed out — a net gain of 13 holders — while 43 added to existing stakes and 23 trimmed.
The largest buyer was Millennium Management, adding an estimated $6.9M. The largest seller was Janus Henderson Group, exiting entirely with an estimated $13.1M sold.
- 116 institutional investors held Larimar Therapeutics (LRMR) as of Q2 2025, up from 103 in Q1 2025.
- Funds reported $180M of Larimar Therapeutics stock for Q2 2025, up 37% quarter-over-quarter.
- 30 funds opened new Larimar Therapeutics positions in Q2 2025 and 17 closed out, a net change of +13 holders.
- The largest Larimar Therapeutics buyer in Q2 2025 was Millennium Management, an estimated $6.9M added.
- The largest Larimar Therapeutics seller in Q2 2025 was Janus Henderson Group, an estimated $13.1M sold.
Based on aggregated 13F filings for Q2 2025.